

S/N 09/150,813

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David J. Grainger et al.

Examiner: Joseph F. Murphy, Ph.D.

Serial No.: 09/150,813

Group Art Unit: 1644

Filed: September 11, 1998

Docket: 295.027US1

Title:

COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN  
INFLAMMATORY RESPONSE



**AMENDMENT AND RESPONSE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on February 23, 2000, please amend the above-identified application as follows:

**In the Specification**

On a separate page, following the claims, please insert the following:

**-- Abstract of the Invention**

Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided. --.

**In the Claims**

Please cancel claims 1-16, 18-19, 23, 29-30, 36-39, 46-47, and 51 without prejudice.

Please amend the following claims:

17. (Amended) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a [chemokine peptide 3] peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1, and wherein the peptide inhibits the response induced by the corresponding native chemokine, [a chemokine peptide 2, a variant thereof, a derivative thereof, or a combination thereof, effective to prevent or inhibit said activity,] wherein the chemokine is not interleukin 8 (IL-8) [IL8] or